Weight-of-Evidence Analysis for the Development of a Reference List of Chemical Respiratory Sensitizers

Ponder, Jessica¹; Rajagopal, Ramya²; Cochrane, Stella²; Singal, Madhuri³; Baker, Nancy⁴; Patlewicz, Grace⁵; Roggen, Erwin⁶; Sullivan, Kristie¹

BACKGROUND


Unmet Regulatory Need

Depending on the regulatory context, approaches are needed for determining the potential of a low molecular weight (LMW) compound to sensitize the respiratory tract and hence the need for hazard labeling, potency assessment, and the definition of sensitization and elicitation thresholds. Approaches are also needed to distinguish respiratory from dermal sensitizers. This unmet need presents a unique opportunity to apply New Approach Methodologies (NAMs) and human biological understanding *ab initio* to develop regulatory guidelines and approaches needed to protect consumer and worker health.


AOP-Driven Criteria

The Adverse Outcome Pathway for respiratory sensitization follows a similar path to dermal sensitization, from protein binding to immune activation [1]. However, these pathways diverge at early key events, resulting in IgE-mediated bronchial hypersensitivity for respiratory sensitizers rather than T cellmediated contact dermatitis. The biological necessity of Key Events in the AOP was used to identify clinical diagnostic criteria for classifying chemical respiratory sensitizers from clinical literature [2].

Scan for



"In Litero" Screening to Identify Clinical **Respiratory Sensitizers**



This approach successfully identified 28 chemicals that can be considered as human respiratory sensitizers and used to evaluate the performance of NAMs as part of a weight of evidence approach to identify novel respiratory sensitizers. A comparison of the protein binding mechanisms of our identified "in litero" clinical respiratory sensitizers shows that acylation is a prevalent protein binding mechanism, in contrast to Michael addition and Schiff base formation common to skin sensitizers [2]. The 153 chemicals with equivocal evidence were prioritized for further evaluation herein based on additional (*in vitro* and in vivo) evidence.










This information does not reflect EPA policy.

- 1. Physicians Committee for Responsible Medicine, Washington, DC, US 2. SEAC, Unilever, Sharnbrook, Bedfordshire, UK
- 3. L'Oreal, Clark, NJ, US

Using our 28 clinical respiratory sensitizers, we have gathered and integrated available in vivo and in vitro sensitization data to develop a list of 49 respiratory sensitizers and 16 non-sensitizers that could be used to evaluate NAMs for RS.

POSITIVE CHEMICALS

In Vitro Dermal Methods are Not Sensitive for Respiratory Sensitizers



Weight-of-Evidence: Identifying Additional Respiratory Sensitizers

Clinical Respiratory Sensitizers





- 4. Leidos, contractor to the US EPA, Research Triangle Park, NC
- 5. US EPA, RTP, Durham, US 6. 3Rs Management and Consulting ApS, Glostrup, Denmark

Likely Respiratory Sensitizers

References

Abstract ID# 4583 Poster ID# P473

NEGATIVES

RS-Negative Reference Chemicals

The AOPs for irritation and sensitization overlap at early key events, therefore inclusion of RS-negatives which do and do not cause dermal sensitization and/or respiratory irritation is needed to identify which methods can discriminate between these AOs.

Potential RS negatives	Protein Reactivity	Irritant	Dermal Sensitizer
citric acid		\checkmark	
n-hexane		\checkmark	
benzoic acid		\checkmark	
4-aminobenzoic acid		\checkmark	
4-hydroxybenzoic acid		\checkmark	
isopropanol		\checkmark	
lactic acid		\checkmark	
salicylic acid		\checkmark	
methyl salicylate		\checkmark	
glycerol	\checkmark	\checkmark	
butoxyethanol	\checkmark	\checkmark	
alpha-terpineol	\checkmark	\checkmark	
(+) alpha pinene	\checkmark	\checkmark	
capsaicin	\checkmark	\checkmark	
eugenol	\checkmark	\checkmark	\checkmark
D-limonene	\checkmark	\checkmark	\checkmark

REFERENCE CHEMICAL LIST

- > Our list of respiratory sensitizers includes low-molecular weight chemicals known to, or suggested to, cause RS in humans based on epidemiological reports, protein binding alerts for the chemical or its metabolites, and experimental evidence demonstrating induction and/or elicitation of sensitization.
- > Additional considerations for RS reference chemicals will be incorporated to finalize an ideal reference chemical list for the development of RS-specific NAMs:
 - Well-defined chemical structures
 - Commercial availability and cost
 - Vehicle solubility and compatibility
 - Representation of material forms: *e.g.* solid, liquid
 - Representation of protein binding reactivity: unreactive, soft electrophiles, hard electrophiles
 - Lack of acute toxicity: minimize hazards of handling and disposal

. Lalko, J. F., Kimber, I., Dearman, R. J., Api, A. M. & Gerberick, G. F. 2013. The selective peptide reactivity of chemical respiratory allergens under competitive and non-competitive conditions. J Immunotoxicol, 10, 292-301 Natsch, A., Ryan, C. A., Foertsch, L., Emter, R., Jaworska, J., Gerberick, F. & Kern, P. 2013. A dataset on 145 chemicals tested in alternative assays for skin sensitization undergoing prevalidation. J Appl Toxicol, 33, 1337-52. Basketter, D., Poole, A. & Kimber, I. 2017. Behaviour of chemical respiratory allergens in novel predictive methods for skin sensitisation. Regul Toxicol Pharmacol, 86, 101-106. 5. Urbisch, Daniel, Annette Mehling, Katharina Guth, Tzutzuy Ramirez, Naveed Honarvar, Susanne Kolle, Robert Landsiedel, et al. "Assessing Skin Sensitization Hazard in Mice and Men Using Non-Animal Test Methods." Regulatory Toxicology and Pharmacology 71, no. 2 (2015/03/01/ 2015): 337-51. 7. OECD QSAR Toolbox v4.5

^{1.} Sullivan K, Enoch S, Ezendam J, Sewald K, Roggen E, and Cochrane, S. Applied In Vitro Toxicology. Sep 2017.213-2. Ponder J, Rajagopal R, Singal M, Baker N, Patlewicz G, Roggen E, Cochrane S, Sullivan K. 2022. Frontiers in Toxicology 4:916370